Zephyr’s chief medical officer will take home two American Academy of Dental Sleep Medicine awards next month.
John E. Remmers, MD, chief medical officer of Zephyr Sleep Technologies, has been selected as a recipient of the American Academy of Dental Sleep Medicine (AADSM) Clinical Research Award and the AADSM Clinical Excellence Award for 2016. He was selected based on the scientific merit and research excellence demonstrated in the abstract “A Mandibular Positioning Home Sleep Test Prospectively Predicts Outcome of Oral Appliance Therapy for OSA Using Retrospectively Derived Decision Criteria.”
In addition, Nikola Vranjes, DDS, principal dental investigator in this clinical trial using the auto-titrating mandibular positioner (AMP) technology, has been selected as a recipient of the AADSM Clinical Research Award for the scientific merit of the abstract “A New Oral Appliance Titration Protocol using the MicrO2 Sleep Device and Mandibular Positioning Home Sleep Test.”
These awards will be presented to Remmers and Vranjes at AADSM 25th Anniversary Meeting in Denver.
Frustrated with the field’s inability to embrace alternatives to CPAP, Remmers and colleagues from the University of Calgary and local business leaders co-founded Zephyr Sleep Technologies in 2010 to create innovative ways to diagnose and treat illnesses relating to sleep-disordered breathing.
Oral appliance therapy (OAT) has emerged as a treatment alternative to CPAP, but lacks a standard and scientifically-validated method to select patients for this treatment. Patient selection for OAT is critical as it is not efficacious in everyone.
In 2012, Zephyr Sleep Technologies released MATRx, an in-lab OAT titration system. To date, the MATRx in-lab study has been performed on approximately 10,000 patients. “By selecting patients for OAT with MATRx, MDs are now able to confidently prescribe an oral appliance to treat OSA,” says Remmers in release. “Once we take a patient’s preference for OAT and higher adherence into account, we will be able to treat a greater number of patients.”
Zephyr has long been hinting that it will be releasing an at-home version of the Matrx. “By opening the door to bringing MATRx to the patient’s home, we believe we will increase accessibility and provide structural cost benefit to the healthcare system,” says Paul Cataford, CEO and co-founder of Zephyr. “We have a lot of exciting announcements coming over the next few months, so, stay tuned.”
The post Study About Predicting Oral Appliance Efficacy Wins AADSM Awards appeared first on Dental Sleep Corner.
